Details of the Drug

General Information of Drug (ID: DM3XU74)

Drug Name

Dornase Alfa

Synonyms

Pulmozyme (TN)

Indication

Disease Entry	ICD 11	Status	REF
Cystic fibrosis	CA25	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Enzyme Replacement Agents

Affected Organisms

Humans and other mammals

Sequence

LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAP
DTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFS
RFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQ
WSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYG
LSDQLAQAISDHYPVEVMLK

ADMET Property

Metabolism: The drug is metabolized via proteases in biofluids []

Cross-matching ID

UNII: 953A26OA1Y
DrugBank ID: DB00003
TTD ID: D0JE4D

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Breaker	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	ClinicalTrials.gov (NCT04359654) Nebulised Dornase Alfa for Treatment of COVID-19. U.S. National Institutes of Health.
3	Dornase alfa. BioDrugs. 1997 Dec;8(6):439-45.